Treatment-resistant schizophrenia Mental and Behavioural Disorders
Conditions
Interventions
Participants were randomly divided into a control group and a study group, with the control group receiving risperidone tablets and psychotherapy, and the study group undergoing MECT as well as the co
Chinese Pharmacopoeia Registration Number H20010309)
The Thymatron® System IV (America)
1 mg of atropine (Wuhu Kangqi Pharmaceutical Co., Ltd., Wuhu China
Chinese Pharmacopoeia Registration Number H34021900)
1.5 mg/kg propofol (Guangdong Jiabo Pharmaceutical Co., Ltd., Guangdong China
Chinese Pharmacopoeia Registration Number H20051843)
1–1.5 mg/kg of succinylcholine chloride (Shanghai Xudong Haipu Pharmaceutical Co., Ltd., Shanghai China
Chinese Pharmacopoeia Registration Number H31020599)
Sponsors
Wuhan Wudong Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >18 years old 2. With complete medical records 3. With Positive and Negative Syndrome Scale (PANSS) scores for both positive and negative symptoms >60 points 4. With a clinical diagnosis of TRS 5. Who had had TRS for >5 years 6. Who had had previous treatment with 2 or more antipsychotic drugs of different chemical structure, each at a sufficient dosage, with no significant improvement after continuous treatment for more than 2 months 7. Those who did not show drug intolerance or maladaptation during the course of this study
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of positive and negative symptoms assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and 2 months after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured before treatment and 2 months after treatment: 1. Anxiety and depression measured using the Hamilton Anxiety Rating Scale (HAMA) and the Hamilton Depression Rating Scale (HAMD) 2. Severity of trauma exposure measured using the Traumatic Exposure Severity Scale (TESS) 3. Severity of disease measured using the Brief Psychiatric Rating Scale (BPRS) 4. Memory measured using the Wechsler Memory Scale (WMS) | — |
Countries
China
Contacts
Public ContactQiu-Ming Ji
Outcome results
None listed